PHENOMENAL

OFFICIAL TITLE: MULTICENTER OPEN-LABEL, PHASE II TRIAL, TO EVALUATE THE EFFICACY AND SAFETY OF NAL-IRI FOR PROGRESSING BRAIN METASTASES IN PATIENTS WITH HER2-NEGATIVE BREAST CANCER (THE PHENOMENAL STUDY).

PROJECT DETAILS

MULTICENTER OPEN-LABEL, PHASE II TRIAL, TO EVALUATE THE EFFICACY AND SAFETY OF NAL-IRI IN PATIENTS WITH HER2-NEGATIVE BREAST CANCER, WHO HAVE DOCUMENTED CENTRAL NERVOUS SYSTEM (CNS) PROGRESSION FOLLOWING WHOLE BRAIN RADIO THERAPY (WBRT), STEREOTACTIC RADIOSURGERY (SRS) AND/OR SURGERY, AS DETERMINED BY THE RESPONSE ASSESSMENT IN NEURO-ONCOLOGY BRAIN METASTASES (RANO-BM) CRITERIA.

 

PHENOMENAL AT CLINICALTRIALS.GOV

TUMOR TYPE

PHASE

HER2-NEGATIVE MBC

II

26

18

Spain

Recruiting

N

SITES

COUNTRY

STATUS

AACR 2018 – DOWNLOAD THE POSTER

PHENOMENAL SITES

SPAIN

Instituto Oncológico Baselga - Hospital Quiron Salud Barcelona

SPAIN

Hospital Universitari Sant Joan de Reus

SPAIN

Hospital Universitario Ramón y Cajal

SPAIN

Instituto Valenciano de Oncología (IVO)

SPAIN

Hospital Universitario Virgen del Rocío

SPAIN

Complejo Hospitalario Universitario de Santiago (CHUS)

SPAIN

Institut Català d' Oncologia Girona (ICO)

SPAIN

Hospital Universitario Miguel Servet

SPAIN

Institut Català d' Oncologia Badalona (ICO)

SPAIN

Hospital Universitario Virgen de la Victoria

SPAIN

Hospital Parc Taulí

SPAIN

MD Anderson Cancer Center Madrid

SPAIN

Hospital Clínico San Carlos

SPAIN

Hospital Universitario Doce de Octubre

SPAIN

Hospital San Pedro de Alcántara

SPAIN

Hospital Universitari Son Espases

SPAIN

Hospital Son Llatzer